PRESS RELEASE published on 08/28/2023 at 13:30, 2 years 7 months ago NLS Pharmaceutics CEO Issues Letter to Shareholders
PRESS RELEASE published on 05/02/2023 at 14:45, 2 years 11 months ago NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
PRESS RELEASE published on 03/27/2023 at 14:30, 3 years ago NLS Pharmaceutics Announces Open Label Extension Study Six-Month Data for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy Type 1 and Type 2
PRESS RELEASE published on 01/23/2023 at 14:30, 3 years 2 months ago NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
PRESS RELEASE published on 01/12/2023 at 14:30, 3 years 3 months ago NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
Published on 04/17/2026 at 02:00, 9 minutes ago UraniumX Announces Closing Of Final Tranche Of Non-Brokered Private Placement
Published on 04/16/2026 at 23:32, 2 hours 37 minutes ago Zomedica Announces “Fourth Friday at Four” Webinar on April 24th: A Behind-the-Scenes Look at Manufacturing Excellence and Operational Scale
Published on 04/16/2026 at 21:30, 4 hours 39 minutes ago Organto Foods Expands Financing Facilities with Rabobank
Published on 04/16/2026 at 15:20, 10 hours 49 minutes ago Datavault AI Goes Live with First Edge GPU Sites in New York and Philadelphia; $1.44B-$1.92B Quantum-Ready Fleet to Reach 100+ U.S. Cities by End of 2026
Published on 04/16/2026 at 23:40, 2 hours 28 minutes ago Coventry Ranks #1 in 2025 Life Settlement League Table Report
Published on 04/16/2026 at 21:37, 4 hours 31 minutes ago Approval of the Offer Document concerning the voluntary tender offer for shares of NEXT RE SIIQ S.p.A.
Published on 04/16/2026 at 21:00, 5 hours 8 minutes ago Vizrt AI Keyer kills the green screen and creates virtual scenes in any environment
Published on 04/16/2026 at 20:35, 5 hours 33 minutes ago EQS-Adhoc: Correction of a release from 16/04/2026, 19:17 CET/CEST - Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 19:17, 6 hours 51 minutes ago EQS-Adhoc: Drägerwerk AG & Co. KGaA: Preliminary figures Q1 2026: Earnings significantly above prior year
Published on 04/16/2026 at 18:02, 8 hours 7 minutes ago Covivio - Description of the share buy-back program authorized by the Combined Ordinary and Extraordinary Shareholders’ Meeting held on 16 April 2026
Published on 04/16/2026 at 17:54, 8 hours 14 minutes ago Aéroports de Paris S.A - March 2026 traffic figures
